OR WAIT null SECS
November 16, 2020
The companies will work together on research activities through to the selection of a preclinical candidate, after which Roche will handle further development and global commercialization.
November 12, 2020
Apeiron Biologics has selected Domainex to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b.
PhoreMost and Oxford Biomedica have entered into a discovery collaboration for the development of next-generation chimeric antigen receptor T-cell therapies.
November 10, 2020
FDA issued emergency use authorization for bamlanivimab for patients at risk for severe COVID-19.
November 09, 2020
Interim efficacy data suggests the Pfizer/BioNTech has an efficacy rate above 90%.
November 06, 2020
ProteoNic has licensed its protein expression technology, 2G UNic, to Gilead Sciences.
Lonza has inaugurated its first ADC payload manufacturing suite at the Visp, Switzerland site.
November 04, 2020
Sanofi’s Digitally Enabled Integrated Continuous Biomanufacturing Facility in Framingham, MA was named the Overall Award winner at the ISPE virtual annual meeting.
November 03, 2020
The agreement will provide capacity for the manufacturing of AZD7442, currently being developed for the potential prevention and treatment of COVID-19, at Lonza's Portsmouth, NH site.
October 29, 2020
NanoMab Technology has signed heads of terms with a supplier of Tungsten-188/Rhenium-188 generators, OncoBeta.